Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks heat therapy for kidney tumors

NCT ID NCT07465458

Disease control Sponsor: Humanitas Hospital, Italy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watches 226 adults with small kidney tumors (stage T1a) who get radiofrequency ablation, a treatment that uses heat to destroy cancer cells. Researchers will track how well the procedure works and any side effects. No extra treatments or tests are given—just normal care is observed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 226 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Mar 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with primary renal cell carcinomas in stage T1a

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient selection criteria will be those typically established by each participating center t with T1a primary renal tumors for which a Multidisciplinary Tumor Board has indicated as candidates for treatment with radiofrequency ablation.I Inclusion Criteria: * Age ≥18 years * Signed informed consent approved by the Ethics Committee prior to the ablation procedure. * RCC in stage T1a (size \<4 cm), single or multiple, histologically demonstrated by percutaneous biopsy before or within 30 days prior to ablation * Absence of comorbidities that contraindicate treatment * Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0-2 at baseline screening. Exclusion Criteria: * No specific exclusion criteria are established for this clinical registry due to its observational nature. Each center will apply its own criteria according to its routine clinical practice.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Renal carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

renal carcinoma renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Renal carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    10 sites in 2 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Fondazione Poliambulanza Istituto Ospedaliero

    Brescia, Italy

  • Hospital Clínico Universitario

    Barcelona, Spain

  • Hospital Universitario Donostia

    San Sebastián, Spain

  • Hospital Universitario Fundación Jiménez Díaz

    Madrid, Spain

  • Hospital Universitario Puerta de Hierro

    Madrid, Spain

  • Hospital Universitario Reina Sofía

    Córdoba, Spain

  • Hospital Universitario de Leganés (Severo Ochoa)

    Madrid, Spain

  • IRCCS Ospedale San Raffaele

    Milan, Milano, Italy

  • Istituto Europeo di Onclologia ( IEO)

    Milan, Italy

  • Policlinico Universitario Campus Bio-Medico

    Roma, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.